The European Union has granted CE mark certification to Apollo Endosurgery’s endoscopic surgical platform, designed to offer less invasive options during various endoscopic surgical procedures.

Combining the flexibility of endoscopy with the precision of surgical suturing, the OverStitch endoscopic suturing system allows clinicians to access, manipulate and suture internal tissue without making incisions through the skin, while treating defects in the digestive tract, gastrointestinal cancer and bariatrics.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Evangelisches Krankenhause Düsseldorf professor of internal medicine Dr Horst Neuhaus said the new platform also offers potential advantages over open and laparoscopic surgery including lower risk of infection, less post-operative pain, faster recovery time and no visible scars.

“The OverStitch endoscopic suturing system allows clinicians to access, manipulate and suture internal tissue without making incisions through the skin, while treating defects in the digestive tract, gastrointestinal cancer and bariatrics.”

“With this new endoscopic suturing platform, trained physicians can safely perform many procedures endoscopically, from inside, that previously would have required a more traditional surgical approach,” Neuhaus said.

International Federation of Surgery for Obesity president Dr Luigi Angrisani said; “Endoscopic suturing with the OverStitch device provides great potential to transform how we treat the bariatric patient by offering new less invasive endoscopic approaches for both early intervention and the treatment of complications from previous surgical weight loss procedures.”

Apollo Endosurgery is planning to launch the system in selected centres in several European countries.

The company is also working with several European countries distributors to identify interventional gastroenterologists and surgeons to participate in the initial phase of the European launch.

Apollo Endosurgery president and CEO Dennis McWilliams said the company believes that endoscopic platform will positively impact the lives of millions of patients in the European market.

“Apollo Endosurgery will continue to strive towards maintaining its leadership position as an innovator and a driving force in advancing this new class of less invasive therapies,” McWilliams said.